Inoue, Daichi
Chew, Guo-Liang
Liu, Bo
Michel, Brittany C.
Pangallo, Joseph
D’Avino, Andrew R.
Hitchman, Tyler
North, Khrystyna
Lee, Stanley Chun-Wei
Bitner, Lillian
Block, Ariele
Moore, Amanda R.
Yoshimi, Akihide
Escobar-Hoyos, Luisa
Cho, Hana
Penson, Alex
Lu, Sydney X.
Taylor, Justin
Chen, Yu
Kadoch, Cigall
Abdel-Wahab, Omar
Bradley, Robert K.
Article History
Received: 12 January 2019
Accepted: 30 August 2019
First Online: 9 October 2019
Competing interests
: C.K. is a Scientific Founder, fiduciary Board of Directors member, Scientific Advisory Board member, consultant and shareholder of Foghorn Therapeutics, none of which are related to the current manuscript. O.A.-W. has served as a consultant for H3 Biomedicine, Foundation Medicine, Merck and Janssen; O.A.-W. has received personal speaking fees from Daiichi Sankyo. O.A.-W. has received previous research funding from H3 Biomedicine unrelated to the current manuscript. D.I., O.A.-W. and R.K.B. are inventors on a provisional patent application submitted by the Fred Hutchinson Cancer Research Center that covers BRD9 activation in cancer.